Search - tctmd.com

Displaying 1 - 20 of 44

Sort: Relevancy | Date

Presentation TCT 2025

Perspective 3: That Could be DanGer-ous: Impella CP is the Way to Go

Presenter: Marwan F. Jumean

October 28, 2025

Presentation TCT 2025

TCT 258: Age and Sex Modify Long-Term Benefit of Microaxial Flow Pump Treatment in Cardiogenic Shock: A DanGer Shock Analysis

Presenter: Anika Klein

October 27, 2025

Presentation TCT 2025

The Contemporary Management of Cardiogenic Shock in the Post DanGer-Shock Era?

Presenter: Jacob Eifer Moeller

October 27, 2025

Presentation TCT 2025

TCT 284: Geographic Disparities in Mechanical Circulatory Support Use Following the DanGer Shock Trial: Insights from the Epic Cosmos Database

Presenter: Karnav Modi

October 27, 2025

Presentation TCT 2025

DanGer Long Term Data ESC: Evidence in the Post DanGer Era

Presenter: Daniel Burkhoff

October 27, 2025

Presentation TCT 2025

TCT 277: Characteristics and Clinical Outcomes of DanGer Shock-Like and Non–DanGer Shock-Like Patients in AMICS Treated With Impella Support: Insights from RECOVER III and NCSI Registries

Presenter: Batla Falah

October 27, 2025

Presentation TCT 2025

TCT 279: Clinical Characteristics of Patients Eligible for the DanGer Shock Trial in a Single-Center ACS Cohort

Presenter: Kohei Osakada

October 27, 2025

Presentation TCT 2025

TCT 272: Escalation of Mechanical Circulatory Support in non-comatose Patients with STEMI-related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial

Presenter: Norman Mangner

October 27, 2025

Presentation TCT 2025

TCT 255: A Novel Cardiogenic Shock Score Based On Danger shock trial

Presenter: Narumi Irie

October 26, 2025

Presentation TCT 2025

TCT 1543: "Arm"ed and (not so) Dangerous: Axillary Artery Impella CP Assisted Left Main PCI

Presenter: Siva Ketha

October 26, 2025

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

Caitlin E. Cox

October 31, 2024

Presentation TCT 2024

DANGER Shock: Impella versus Standard Card for STEMI Patients with Cardiogenic Shock

Presenter: Jacob Moeller

October 30, 2024

Presentation TCT 2024

TCT 272: DANGER Shock Trial Versus Real-World Use of Microaxial Flow Pump in STEMI-Related Cardiogenic Shock

Presenter: Jack Jnani

October 29, 2024

Presentation TCT 2024

TCT 273: DanGer Shock-Like Profile Predicts the Outcome of Patients With ST-Elevation Myocardial Infarction Related Cardiogenic Shock

Presenter: Norman Mangner

October 29, 2024

Presentation TCT 2024

TCT 269: Insights From the Danger-SHOCK and ECLS-Shock Trials: A Comparative Analysis

Presenter: Giuseppe Tarantini

October 29, 2024

Presentation TCT 2024

Results of DanGer Shock: Risks and Benefits of MCS for Cardiogenic Shock Put Into Perspective

Presenter: Jacob Moeller

October 29, 2024

Presentation TCT 2024

Ways in Which DanGer Will and Will Not Influence Clinical Practice in the EU

Presenter: Jose Henriques

October 29, 2024

Presentation TCT 2024

A Mandate to Generate Evidence for the Use of Temporary Support Devices in Decompensated Chronic Heart Failure Shock

Presenter: Jane Wilcox

October 29, 2024

Presentation TCT 2024

Ways in which DanGer Will and Will Not Influence Clinical Practice in the US

Presenter: David Morrow

October 29, 2024

Presentation TCT 2024

TCT 267: Impact of Microaxial Flow Pump on Central Hemodynamics and Use of Vasoactive Drugs During Intensive Care After Infarct-Related Cardiogenic Shock: A Secondary Analysis of the Danger Shock Trial

Presenter: Nanna Louise Junker Udesen

October 29, 2024

Advertisement

Perspective 3: That Could be DanGer-ous: Impella CP is the Way to Go

TCT 258: Age and Sex Modify Long-Term Benefit of Microaxial Flow Pump Treatment in Cardiogenic Shock: A DanGer Shock Analysis

The Contemporary Management of Cardiogenic Shock in the Post DanGer-Shock Era?

TCT 284: Geographic Disparities in Mechanical Circulatory Support Use Following the DanGer Shock Trial: Insights from the Epic Cosmos Database

DanGer Long Term Data ESC: Evidence in the Post DanGer Era

TCT 277: Characteristics and Clinical Outcomes of DanGer Shock-Like and Non–DanGer Shock-Like Patients in AMICS Treated With Impella Support: Insights from RECOVER III and NCSI Registries

TCT 279: Clinical Characteristics of Patients Eligible for the DanGer Shock Trial in a Single-Center ACS Cohort

TCT 272: Escalation of Mechanical Circulatory Support in non-comatose Patients with STEMI-related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial

TCT 255: A Novel Cardiogenic Shock Score Based On Danger shock trial

TCT 1543: "Arm"ed and (not so) Dangerous: Axillary Artery Impella CP Assisted Left Main PCI

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

DANGER Shock: Impella versus Standard Card for STEMI Patients with Cardiogenic Shock

TCT 272: DANGER Shock Trial Versus Real-World Use of Microaxial Flow Pump in STEMI-Related Cardiogenic Shock

TCT 273: DanGer Shock-Like Profile Predicts the Outcome of Patients With ST-Elevation Myocardial Infarction Related Cardiogenic Shock

TCT 269: Insights From the Danger-SHOCK and ECLS-Shock Trials: A Comparative Analysis

Results of DanGer Shock: Risks and Benefits of MCS for Cardiogenic Shock Put Into Perspective

Ways in Which DanGer Will and Will Not Influence Clinical Practice in the EU

A Mandate to Generate Evidence for the Use of Temporary Support Devices in Decompensated Chronic Heart Failure Shock

Ways in which DanGer Will and Will Not Influence Clinical Practice in the US

TCT 267: Impact of Microaxial Flow Pump on Central Hemodynamics and Use of Vasoactive Drugs During Intensive Care After Infarct-Related Cardiogenic Shock: A Secondary Analysis of the Danger Shock Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content